Search bioRxiv⌕ Search

Biology subjects

Vadadokhau, U.

Publications and source records attributed to Vadadokhau, U..

2 recordsLinked to original sources
bioRxiv2026

CoPISA: Combinatorial Proteome Integral Solubility/Stability Alteration analysis

Combination therapies are widely used in acute myeloid leukemia (AML), but systematic datasets capturing proteome-wide responses to multi-drug perturbations remain limited. Here we present CoPISA (Combinatorial Proteome Integral Solubility/Stability Alteration), a quantitative proteomics assay designed to profile protein solubility and stability responses to single and combined drug treatments. The dataset includes two AML drug pairs (LY3009120-sapanisertib and ruxolitinib-ulixertinib) applied to four AML cell lines (MOLM-13, MOLM-16, SKM-1, and NOMO-1) under control, single-agent, and combination conditions in both lysate and intact-cell formats. Thermal solubility profiling coupled with TMT-based multiplexed LC-MS/MS generated 16 TMT16-plex experiments comprising 192 LC-MS/MS raw files, providing deep proteome coverage across treatments and biological contexts. The resource includes raw and processed proteomics data, detailed experimental metadata in Sample and Data Relationship Format (SDRF), and reproducible analysis scripts for reporter normalization, protein-level aggregation, statistical modeling, and classification of combinatorial response patterns. The experimental design enables identification of proteins responding uniquely to combination treatments as well as overlapping single-agent effects. Technical validation demonstrates reproducible quantification across multiplex experiments and assay formats. All data are publicly available through the PRIDE repository (PXD066812) together with analysis code, enabling independent reanalysis and method development. This dataset provides a benchmark resource for studying proteome responses to drug combinations, comparing lysate and intact-cell perturbation profiles, developing computational approaches for combinatorial target inference, and supporting training in computational proteomics.

bioinformatics↗
bioRxiv2024

Exploring Mechanisms of Action in Combinatorial Therapy through Stability/Solubility Alterations: Advancing AML Treatment

Acute myeloid leukemia (AML) remains a formidable clinical challenge due to genetic heterogeneity, high relapse rates, and toxicities associated with conventional chemotherapies. Rationally designed drug combinations offer improved efficacy, yet their selection is often empirical and lacks molecular mechanistic understanding. Here, we present CoPISA workflow (Proteome Integral Solubility/Stability Alteration Analysis for Combinations), a high-throughput proteomics workflow that captures protein solubility/stability alterations unique to combinatorial drug treatments, revealing mechanisms unattainable through single-drug analyses. Applying CoPISA to two rationally designed AML drug pairs, LY3009120-sapanisertib (LS) and ruxolitinib-ulixertinib (RU), we mapped primary (lysate) and secondary (living cell) protein target landscapes. Notably, our analysis uncovered an emergent mechanistic principle, "conjunctional targeting" (i.e., conjunctional inhibition), wherein cooperative drug actions induce treatment-specific targets not achievable individually, analogous to an AND-gate logic model. LS-specific AND-gate proteins converged on SUMOylation, chromatin condensation, and VEGF-linked adhesion, while RU-specific targets disrupted DNA-damage checkpoints, mitochondrial bioenergetics, and RNA-splicing machinery, collectively implicating synthetic-lethal vulnerabilities. Additionally, the post-translational modifications (PTMs) profiling of differential soluble proteins confirms several combination-induced modifications (e.g., acetylation, dimethylation, phosphorylation) on key AML proteins, such as NPM1. Network interrogation of AML-associated proteins showed that a high percentage of targeted proteins are unique to the combinations, including frequently mutated drivers DNMT3A, NPM1, and TP53. CoPISA exposes how drug pairs enact multi-axis pressure on AML cells through conjunctional targeting, a mechanistic layer beyond classical synergy. By pinpointing combination-exclusive protein targets and signaling pathways, CoPISA provides a blueprint for precision-guided regimen design in AML and other heterogeneous cancers. Data are available via ProteomeXchange with identifier PXD066812.

biochemistry↗